David Volkin

David Volkin joined the KU faculty in 2010, after a 20-year career in the vaccine and biopharmaceutical industry, including senior director positions at Merck Research Laboratories (Merck) and Centocor R&D (J&J). He led groups responsible for analytical and formulation development of vaccines and therapeutic protein drugs. He has contributed to bringing dozens of candidates into human clinical trials, including five vaccines and three monoclonal antibody drugs now approved for commercial use. He is co-author of ~135 scientific publications and co-inventor on 15 U.S. patents, including the stabilization and formulation of the commercial human papillomavirus (Gardasil®) and rotavirus (RotaTeq®) vaccines. He was awarded the American Association of Pharmaceutical Scientists (AAPS) Research Achievement Award in Biotechnology in 2015.

One of 34 U.S. public institutions in the prestigious Association of American Universities
44 nationally ranked graduate programs.
—U.S. News & World Report
Top 50 nationwide for size of library collection.
5th nationwide for service to veterans —"Best for Vets: Colleges," Military Times
KU Today

Our research projects ranging from traditional pharmaceutics to biotechnology. 

Learn more here.